Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, 310006, China.
Integrated Traditional Chinese and Western Medicine Oncology Laboratory, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Clin Transl Oncol. 2023 Dec;25(12):3527-3540. doi: 10.1007/s12094-023-03222-5. Epub 2023 May 30.
Although aberrant expression of CDGSH iron sulfur domain 2 (CISD2) contributes to the tumorigenesis and progression of numerous human cancers, the biological function of CISD2 and its specific prognostic value in lung squamous cell carcinoma (LUSC) have yet to be comprehensively explored. The current study aimed to elucidate the role of CISD2 in LUSC as well as the underlying molecular mechanisms.
Immunohistochemistry was conducted to detect the protein expression of CISD2 and analyze whether high expression of CISD2 affects the overall survival (OS) of LUSC patients. Cell proliferation, colony formation, wound healing and Transwell invasion assays were performed to clarify whether CISD2 contributes to LUSC cell proliferation and disease progression. Quantitative real-time reverse transcription-PCR and western blot assays were used to detect the levels of transcription factors and key epithelial-mesenchymal transition (EMT)-related markers in LUSC cells after CISD2 knockdown and overexpression to determine whether CISD2 regulates transforming growth factor-beta (TGF-β)-induced EMT in LUSC.
Immunohistochemistry of human tissue microarrays containing 90 pairs of adjacent and cancerous tissues revealed that CISD2 is considerably overexpressed in LUSC and strongly linked to poor OS. Functional experiments suggested that silencing endogenous CISD2 inhibited the growth, colony formation, migration, and invasion of H2170 and H226 cell lines. Exogenous overexpression of CISD2 facilitated these phenotypes in SK-MES-1 and H2170 cells. Furthermore, CISD2 promoted EMT progression by increasing the expression of mesenchymal markers (N-cadherin, vimentin, Snail, and Slug) as well as SMAD2/3 and reducing the expression of the epithelial marker E-cadherin. Mechanistically, our studies provide the first evidence that CISD2 can promote EMT by enhancing TGF-β1-induced Smad2/3 expression in LUSC cells.
In conclusion, our research illustrates that CISD2 is highly expressed in LUSC and may facilitate LUSC proliferation and metastasis. Thus, CISD2 may serve as an independent prognostic marker and possible treatment target for LUSC.
尽管 CDGSH 铁硫结构域 2(CISD2)的异常表达有助于许多人类癌症的发生和发展,但 CISD2 的生物学功能及其在肺鳞状细胞癌(LUSC)中的具体预后价值尚未得到全面探讨。本研究旨在阐明 CISD2 在 LUSC 中的作用以及潜在的分子机制。
通过免疫组织化学检测 CISD2 的蛋白表达,并分析 CISD2 的高表达是否影响 LUSC 患者的总生存期(OS)。通过细胞增殖、集落形成、划痕愈合和 Transwell 侵袭实验,阐明 CISD2 是否有助于 LUSC 细胞增殖和疾病进展。通过定量实时逆转录-PCR 和 Western blot 检测 CISD2 敲低和过表达后 LUSC 细胞中转录因子和关键上皮-间充质转化(EMT)相关标志物的水平,以确定 CISD2 是否调节 LUSC 中的转化生长因子-β(TGF-β)诱导的 EMT。
包含 90 对相邻癌组织的人组织微阵列的免疫组织化学显示,CISD2 在 LUSC 中过表达,与不良 OS 强烈相关。功能实验表明,沉默内源性 CISD2 抑制了 H2170 和 H226 细胞系的生长、集落形成、迁移和侵袭。外源性过表达 CISD2 促进了 SK-MES-1 和 H2170 细胞的这些表型。此外,CISD2 通过增加间充质标志物(N-钙粘蛋白、波形蛋白、Snail 和 Slug)以及 SMAD2/3 的表达和降低上皮标志物 E-钙粘蛋白的表达来促进 EMT 进展。机制上,我们的研究首次提供了证据表明,CISD2 可以通过增强 LUSC 细胞中 TGF-β1 诱导的 Smad2/3 表达来促进 EMT。
总之,我们的研究表明 CISD2 在 LUSC 中高表达,可能促进 LUSC 的增殖和转移。因此,CISD2 可能作为 LUSC 的独立预后标志物和潜在的治疗靶点。